

# BIOSIG TECHNOLOGIES, INC.

## OFFICIAL COMPANY NEWSLETTER

Issue 6 | October 2021



## A MESSAGE FROM OUR LEADERSHIP

*By Ken Londoner, CEO & Co-Founder, BioSig Technologies, Inc.*

*October has been an exciting month for BioSig, beginning with the official announcements of the PURE EP 2.0 Study published in the Journal of Cardiovascular Electrophysiology. In order for any new medical technology to be widely adopted and accepted, strong, prospective clinical study results are necessary. Based on these outstanding study results, we can confidently confirm that our technology is indeed setting a new standard in electrophysiology. We look forward to sharing more details about the clinical relevance of our clinical study results at the live, physician led, webinar roundtable on November 18, 2021: PURE EP 2.0 Study Results: From Clinical Data to Clinical Applications.*

*More recently, Biosig closed out the month of October with the announcement that we have, again, increased PURE EP<sup>™</sup>'s case volume estimates having exceeded our procedural target of 1500 patient cases in 2021. As of October 21, 2021, the PURE EP<sup>™</sup> System has been used in over 1560 patient cases by 71 physicians, up from 1000 cases in June 2021*

*Other October highlights include BioSig's participation at the Annual International Symposium on Ventricular Arrhythmia; updates about our new manufacturing partnership with global manufacturing and supply chain leader, Plexus Corp.; and the latest webinar series you don't want to miss by our co-developed non-profit organization, the Alliance for Advancing Bioelectronic Medicine!*

*Thank you for supporting BioSig's journey and mission and stay tuned for many more exciting updates this fall!*

## WHAT'S INSIDE:

BIOSIG INCREASES CASE  
VOLUME ESTIMATES

ABOUT THE PURE EP<sup>™</sup> SYSTEM

PURE EP CLINICAL DATA  
PUBLISHED IN LEADING EP  
JOURNAL

SAVE THE DATE  
**PURE EP 2.0 STUDY RESULTS  
FROM CLINICAL DATA TO  
CLINICAL APPLICATION**

THE ANNUAL INTERNATIONAL  
SYMPOSIUM ON VENTRICULAR  
ARRHYTHMIA

#WORLDSTROKEDAY

OCTOBER TEAM WORK  
HIGHLIGHTS & HONORARY  
MENTIONS





## BIOSIG INCREASES CASE VOLUME ESTIMATES

We are proud to report increased adoption and commercial activity of our signal processing technology. As PURE EP™'s adoption increases and the COVID hospitalization rates continue to decline, we are confident with the new case-volume estimate of 1700-1800 procedures by the end of 2021.

“

*We are seeing increased utilization of PURE EP in the 13 hospitals we are currently working in. Physicians recognize value both clinically and economically or they would not be increasing their usage. Hospitals are rapidly scaling their elective procedures and thus we are now seeing increased case volumes and commercial activity.”*

~Ken Londoner, CEO & Co-Founder, BioSig Technologies, Inc.



**PURE EP™**  
Metrics That Matter...

**1560+**  
Patient Cases

**71+**  
Physician Users

**15**  
Clinical Sites

[Learn More](#)

## ABOUT THE PURE EP SYSTEM™

*Better Intelligence Better Outcomes*

The PURE EP™ System offers a novel way to acquire and process cardiac signals. These are essential diagnostic signals that deliver high clinical value in all types of cardiac ablations.

No other systems or technologies preserve the purity of signals physicians need to deliver better outcomes. PURE EP™ was designed to improve clinical decision making by providing the full cardiac picture. When it comes to operating on a patient's heart, there is no room for uncertainty.

# OCTOBER HIGHLIGHTS

# PURE EP CLINICAL DATA PUBLISHED IN THE JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY

This past month we announced that the PURE EP 2.0 Study results have been published in the Journal of Cardiovascular Electrophysiology. The article titled: "Evaluation of a novel cardiac signal processing system for electrophysiology procedures: the PURE EP 2.0 study," further validates the clinical importance of the PURE EP™ system, proving that it is superior to conventional sources of intracardiac signals.

The PURE EP 2.0 study was conducted at three U.S. hospitals: Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital.

“

*It is practically unheard of to have three physicians give you consistent responses in signal analysis. It shows the strong consistency in our results... With these new results, we can now officially say that PURE EP represents a new standard in signal acquisition and processing technology and provides superior physiological intracardiac signals over conventional systems on the market."*

~Julie Stephenson, Vice President, Clinical Affairs, BioSig Technologies, Inc.

[Read the Publication](#)

## Save The Date

### PURE EP 2.0 STUDY RESULTS

### FROM CLINICAL DATA TO CLINICAL APPLICATION

#### A BIOSIG TECHNOLOGIES LIVE ROUNDTABLE WEBINAR

On Thursday, November 18, 2021 from 8:00-9:00 PM EST, BioSig will be hosting a Live Roundtable Webinar to educate listeners about the PURE EP 2.0 Study Results. The webinar will discuss the integration of high-fidelity signals into the current procedural work flow and the impact of advanced signal processing technology on cardiac ablation procedures and beyond.

The Webinar discussion will be led by three leaders in the electrophysiology space, Andrea Natale, MD, Executive Medical Director at St. David's Medical Center, Austin, TX; Wendy Tzou, MD, Director of Electrophysiology, University of Colorado, Denver, CO; & Amin Al-Ahmad, MD, Clinical Electrophysiologist, St. David's Medical Center, Austin, TX.

[Register for the Event](#)

## PURE EP 2.0

### STUDY RESULTS

Results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP signals over the signals from conventional sources.

Overall Signal Quality

**92%**  
**SUPERIOR**  
**OR EQUIVALENT**

Ability to discern near-field vs. far-field

**96%**  
**SUPERIOR**  
**OR EQUIVALENT**

Small, fractionated signals of clinical interest

**95%**  
**SUPERIOR**  
**OR EQUIVALENT**



# A HEALTHY RHYTHM IN OCTOBER



## THE PURE EP™ SYSTEM FEATURED AT THE ANNUAL INTERNATIONAL SYMPOSIUM ON VENTRICULAR ARRHYTHMIA

On October 16th, our technology was featured at the world renown Symposium on Ventricular Arrhythmia (VT). VT 2021 has been developed to meet the educational needs of electrophysiologists, cardiologists, and other physicians and associated professionals interested in the pathophysiology and management of ventricular arrhythmias.

The event was hosted by the University of Pennsylvania Health System's Division of Cardiology and Mount Sinai Hospital's Division of Cardiology; and co-sponsored by The Heart Rhythm Society

“

*Treatments for ventricular arrhythmias have historically been complex due to the very challenging nature of these conditions. We are focusing on uncovering important additional physiologic information to hopefully improve ventricular arrhythmia treatments.”*

~Ken Londoner, CEO & Co-Founder, BioSig Technologies, Inc.

[Learn More About the VT Symposium](#)

## WHAT ARE VENTRICULAR ARRHYTHMIAS?

Ventricular Tachycardia (VT), is a type of ventricular arrhythmia that prevents the heart's ventricles from fully contracting. The longer VT lasts, the greater the risk it could turn into Ventricular Fibrillation (VFib). VFib is one of the most complex and severe abnormal heart rhythm conditions.

During VFib, the heart is incapable of pumping blood, which prevents oxygen flow to the brain and body. VFib has been known to lead to sudden cardiac arrest and instant death, without emergency care.\*

**In the US alone, Ventricular Arrhythmias account for approximately 300,000 Sudden deaths a year**



October 29th marked World Stroke Day, a day to pay awareness to the unprecedented stroke epidemic that is currently sweeping our nation and our globe. People suffering from Atrial Fibrillation have a 5X increased risk of stroke, which equals....

**20%**

*Increased risk of stroke*

**36%**

*Increased risk for those 80+ years old*

**70,000+**

*Ischemic strokes a year caused by Afib*

**#WORLDSTROKEDAY**

[Click Here to Donate to the American Stroke Association](#)





ALLIANCE for ADVANCING  
BIOELECTRONIC MEDICINE

## PRESENTS BIOELECTRONIC MEDICINE TALKS, PART 3: A ROAD MAP FOR THE FUTURE



**Natasha Drapeau**  
*Executive Vice President,  
BioSig Technologies, Inc.  
Founding Member,  
Alliance for Advancing  
Bioelectronic Medicine*



**Dr. Thomas Deering**  
*Chief of the Arrhythmia Center,  
Piedmont Heart Institute  
Former President,  
Heart Rhythm Society*



**Jen French**  
*Senior Editor,  
Neurotech Reports  
Founder,  
Neurotech Network*



**Mario Ottiglio**  
*Managing Director,  
High Lantern Group  
Executive Director,  
Alliance for Advancing  
Bioelectronic Medicine*

Join the Alliance for Advancing Bioelectronic Medicine on Wednesday, November 10, 11am-12pm ET | 17-18 CET for the final episode of our webinar series on the future of bioelectronic medicine – featuring the field's top experts and innovators. Our esteemed panel for Episode 3 includes: Dr. Thomas Deering, Cardiac Electrophysiologist at Piedmont Heart Institute & former President of the Heart Rhythm Society; Jen French, Senior Editor of Neurotech Reports & Founder of the Neurotech Network, & the Alliance for Advancing Bioelectronic Medicine's leadership: Natasha Drapeau & Mario Ottiglio.

**Register Here**

If you missed Episodes 1 & 2 of our webinar series, or just want to learn more about [the most innovative field in healthcare](#), a webcast recording of the Episodes 1 & 2 are available to stream!

**Watch Episodes 1 & 2**

Learn more about the Alliance for Advancing Bioelectronic Medicine at:  
[www.advancingbioelectronicmedicine.org](http://www.advancingbioelectronicmedicine.org)

Or reach out! [info@advancingbioelectronicmedicine.org](mailto:info@advancingbioelectronicmedicine.org)

#BIOELECTRONICMEDICINE

## BIOSIG ATTENDS LOCAL IRIS AFGHAN REFUGEE DRIVE

Members of the BioSig team attended the Westport Rotary Club/ Iris Afghan Refugee Drive in Westport CT, our corporate home-base. BioSig is a proud platinum sponsor for the Westport Rotary Club and our team was thrilled to return to the event this past year in person! Thank you to Katie Bertrum, Executive Assistant and Josh Conroy, Director of Business Development (pictured below) for capturing our team's attendance!



## BIOSIG SETTLES IN AT NEW CORPORATE HEADQUARTERS

Our new Corporate HQ, located in Westport, Connecticut, officially feels like home! On the left, Graham Bonnell, Communications Associate assists Andy Ballou, VP of Investor Relations with office-space set up.



## BIOSIG ABROAD

Chardon Brooks, Communications Associate and Natasha Drapeau, Executive Vice President shared their first face-to-face meet up in picturesque Northern Italy this past month.



## OCTOBER'S HONORARY MENTION

This month we would like to give a special shout-out to our Director of Human Resources, Brenda Castrodad, for her expert guidance and unwavering dedication to source, develop and retain the best talent for our company.

Thank you, Brenda, for your hardwork and dedication to BioSig's growth and success!

## ABOUT BIOSIG TECHNOLOGIES, INC.

BioSig is the bioelectronic intelligence company on a mission to preserve the unaltered value of heart signals, gather and provide the real data physicians need to better control procedures today, and predict better treatment pathways for tomorrow. We are showing the way to help improve outcomes for every patient.

As innovators in the electrophysiology (EP) space, our main focus is addressing the unmet needs of the field. The PURE EP™ System is designed to improve the \$4 billion EP market through a powerful combination of hardware and software that makes better decision-making possible.

Visit our website to learn more: [www.biosig.com](http://www.biosig.com)

Contact us: [info@biosigtech.com](mailto:info@biosigtech.com)



**BioSig**  
technologies

**PURE EP**  
SEE MORE, CLEARLY